2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now

Eli Lilly (NYSE: LLY) has reported an impressive performance for the third quarter, with both revenues and earnings handily beating analysts' consensus estimates. Revenues rose 54% year over year to $17.6 billion, while adjusted earnings per share (EPS) soared by 495% to nearly $7.02. Management is now guiding for revenues of $63 billion to $65 billion in 2025, up from its prior estimated range of $60 billion to $62 billion. The company also expects 2025's adjusted EPS to be in the range of $23 to $23.70, a significant improvement from the previous projection of $21.70 to $23.Image source: Getty ImagesEli Lilly's shares are up 17.5% so far in 2025, modestly outpacing the S&P 500, but the growth story is far from over. Here are two potent reasons why there's still meaningful upside potential for this stock in 2026.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool